Creative Planning Purchases 2,178 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Creative Planning increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,793 shares of the biopharmaceutical company’s stock after buying an additional 2,178 shares during the quarter. Creative Planning’s holdings in Regeneron Pharmaceuticals were worth $12,397,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. West Paces Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on REGN shares. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. Wells Fargo & Company reiterated an “overweight” rating and set a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 23rd. Finally, Leerink Partners reissued a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,116.00.

Regeneron Pharmaceuticals Stock Down 2.2 %

NASDAQ REGN opened at $968.50 on Tuesday. The company has a market cap of $106.72 billion, a price-to-earnings ratio of 28.61, a PEG ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average of $1,106.52 and a 200-day moving average of $1,041.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.79 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.